Culter EG, Bradford EH. Action of iron, cod-liver oil and arsenic on the globular richness of the blood. Am J Med Sci 1878; 75: 74.

Forkner CE and Scott TFM. Arsenic as a therapeutic agent in CML. JAMA 1931; 97: 3.

Stephens DJ and Lawrence JS. The therapeutic effect of solution of potassium arsenite in chronic myelogenous leukemia. Ann Inatern Med 1936; 9: 1488.

Kwong YL, Todd D. Delicious poison: arsenic for the treatment of leukemia Blood 1997; 89: 3487.

Mervis J. Ancient remedy performs new tricks. Science 1996; 273(5275): 578.

32 1992; 12 (3): 170.

72 1996; 17(1): 58.

Shen ZX, Chen GQ, Ni JH, et al. Use of As2O3 in the treatment of acute promyelocytic leukemia (APL): II clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997; 89: 3354.

Soignet SL, Maslak P, Wang ZG, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998; 339: 1341.

Chen GQ, Shi XG, Tang W, et al. Use of As2O3 in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood 1997; 89(9): 3345–3353.

Chen GQ, Zhu J, Shi XG, et al. In vitro studies on cellular and molecular mechanisms of As2O3 in the treatment of APL: As2O3 induces NB4 cell apoptosis with down-regulation of bcl-2 expression and alteration of PML-RARα/PML protein localization. Blood 1996; 88: 1052.

Kitamura K, Yoshida H, Ohno R, et al. Toxic effects of arsenic and other metal ions on APL cells. International J Hematol 1997; 65: 179.

Kitamura K, Kiyoi H, Yoshida H, et al. New retinoids and arsenic for the treatment of refractory APL: Clinical and basic studies for the next generation. Cancer Chemother Pharmacol 1997; 40: 536.

Ochi T, Nakajima F, Sakurai T, et al. Dimethylarsenic acid causes apoptosis in HL-60 cells via interaction with glutathione. Arch Toxicol 1996; 70(12): 815–821.

Shao W, Fanelli M, Ferrara FF, et al. Arsenic trioxide as an inducer of apoptosis and loss of PML/RARα protein in acute promyelocytic leukemia cells. J Natl Cancer Inst 1998; 90(2): 124–133.

Wang ZG, Rivi R, Delva L, et al. Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARα independent manner. Blood 1998; 92(5): 1497–1504.

Konig A, Wrazel L, Warrell Jr RP, et al. Comparative activity of melarsoprol and arsenic trioxide in chronic B-cell leukemia lines. Blood 1997; 90: 562–570.

Zhu XH, Shen YL, Jing YK, et al. Arsenic trioxide (As2O3) induces malignant lymphocyte growth inhibition and apoptosis at clinically achievable concentrations. J Natl Cancer Inst 1999; in press.

Akao Y, Mizoguchi H, Kojima S, et al. Arsenic induces apoptosis in B-cell leukemic cell lines in vitro: activation of caspases and down-regulation of bcl-2 protein. Br J Haematol 1998; 102: 1055–1060.

Zhang W, Ohnishi K, Shigeno K, et al. The induction of apoptosis and cell cycle arrest by arsenic trioxide in lymphoid neoplasms. Leukemia 1998; 12: 1383–1391.

Ishitsuka K, Hanada S, Utsunomiya A, et al. Arsenic trioxide inhibits growth of human T-cell leukemia virus type I infected T-cell lines more effectively than retinoic acids. Br J Haematol 1998; 103: 721–728.

Bazarbachi A, El-Sabban ME, Nasr R, et al. Arsenic and INF synergize to induce cell cycle arrest and apoptosis in human T-cell lymphotropic virus-transformed cells. Blood 1999; 93: 278–283.

Cai X, Shen YL, Chen GQ, et al. As2O3-induced APL cell apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse/cas- pase activation and retinoic acid signaling, in preparation

Yager JW, Wiencke JK, Inhibition of PARP by arsenite. Mutat Res 1997; 386: 345–351.

Lynn S, Shiung JN, Gurr JR, et al. Arsenite stimulates poly(ADP-ribosylation) by generation of nitric oxide. Free Radic Biol Med 1998; 24: 442–449.

Li YM, Broome JD. Arsenic targets tubulins to induce apoptosis in myeloid leukemia cells. Cancer Res 1999; 59(4): 776–780.

Wang TS, Kuo CF, Jan KY, et al. Arsenite induces apoptosis in Chinese hamster ovary cells by generation of reactive oxygen species. J Cell Physiol 1996; 169(2): 256–268.

Chen YC, Lin-Shiau SY, Lin JK. Involvement of reactive oxygen species and caspase 3 activation in arsenite-induced apoptosis. J Cell Physiol 1998; 177(2): 324–333.

Dai J, Weinberg RS, Waxman S, et al. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic through modulation of the glutathione. Blood 1999; 93(1): 268.

Zhu J, Koken MH, Quignon F, et al. Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of APL. Proc Natl Acad Sci USA 1997; 94: 3978–3983.

Muller S, Matunis MJ, Dejean A. Conjugation with the ubiquitin-related modifier SUMO-1 regulates the partitioning of PML within the nucleus. EMBO J 1998; 17: 61–70.

Andre C, Guillemin MC, Zhu J, et al. The PML and PML/RARα domains: from autoimmunity to molecular oncology and from retinoic acid to arsenic. Exp Cell Res 1996; 229: 253–260.

Look AT, Arsenic and apoptosis in the treatment of APL. J Natl Cancer Inst 1998; 21(90): 86–88.

Koken MH, Daniel MT, Gianni M, et al. Retinoic acid, but not arsenic, degrades the PLZF/RARα without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t (11; 17) (q23; q21) APL patient. Oncogene 1999; 18(4): 1113–1118.

Gianni M, Koken MHM, Chelbi-Alix MK, et al. Combined arsenic and RA treatment enhances differentiation and apoptosis in arsenic-resistant NB4 cells. Blood 1998; 91: 4300–4304.